What Фармацитрон Treats: Main Uses and Benefits

This fixed-dose combination product is commonly applied to provide symptomatic relief for the acute, systemic manifestations of viral illness. It is generally used in clinical settings marked by temporary physiological imbalance, and contributes to improved day-to-day comfort and assists with maintaining functional stability during symptomatic periods.

This category of medication is primarily used to temporarily relieve multiple symptoms associated with the common cold and flu-like syndrome.

Management of Systemic Discomfort and Congestion

This domain covers the medication’s role in managing the intensity of systemic discomfort and functional strain. It is relevant for easing fever and generalized body aches, and is applied in addressing symptom clusters related to nasal and sinus congestion. It provides supportive relief, which is relevant when symptoms interfere with routine activities, and supports the patient during episodes of heightened discomfort by easing the overall symptom load.

---

Quick Fact: Symptomatic Management Focus

Feature	Supportive Benefit Context
Relevant Conditions	Common cold, Flu-like syndrome
Symptoms Addressed	Fever, headache, body aches, nasal congestion
Supportive Benefit	Supports comfort, eases symptom load, assists stability
Use Context	Acute symptomatic episodes

Regulatory References

1. DailyMed Label Information

Population Eligibility and Contraindications

The use of Фармацитрон, a fixed-dose combination product, is governed by the eligibility rules for its active ingredients, as specified in regulatory documents.

Eligibility Status	Restriction Condition
Contraindicated	Hypersensitivity to any component (Acetaminophen, Phenylephrine, Ascorbate)
Contraindicated	Concurrent use of Monoamine Oxidase (MAO) inhibitors or use within the last two weeks
Contraindicated	Severe hepatic impairment or severe active liver disease
Contraindicated	Severe or uncontrolled hypertension or severe coronary artery disease
Not Recommended	Children under 12 years of age
Not Recommended	During pregnancy or lactation without consulting a health professional

Eligibility is also restricted for individuals with pre-existing conditions. Caution is advised for patients with high blood pressure, diabetes mellitus, hyperthyroidism, glaucoma, or prostatic enlargement (difficulty urinating). Use is further constrained in cases of severe renal impairment and if there is a history of chronic excessive ethanol consumption or alcoholism, due to the increased risk of liver toxicity. The product must not be taken concurrently with any other medicine containing acetaminophen.

Interactions with other medicines and products

Official regulatory information for this fixed-dose combination product mandates several restrictions regarding co-administration due to potential pharmacokinetic and pharmacodynamic interactions.

Contraindicated Combinations

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is strictly prohibited and must be avoided for at least two weeks after discontinuing MAOI therapy. This restriction is due to the risk of severe pressor effects from the Phenylephrine component. Combining this product with other sympathomimetic decongestants or other medicines containing Acetaminophen is also contraindicated to prevent additive effects and the risk of unintentional overdose, respectively.

Pharmacokinetic and Pharmacodynamic Effects

Interactions involving the Acetaminophen component include enhanced effects of oral anticoagulants (e.g., Warfarin) with prolonged regular use, and altered drug clearance when co-administered with substances like Probenecid or Cholestyramine. Drugs that increase the speed of absorption, such as Metoclopramide, may affect Acetaminophen exposure. The Phenylephrine component's pressor action may be increased by concurrent use of agents such as Tricyclic Antidepressants (TCAs) and certain Cardiac Glycosides.

Substance and Population Constraints

There is a documented risk of severe liver damage associated with the Acetaminophen component when taken concurrently with the chronic, daily consumption of three or more alcoholic drinks. The interaction profile is noted to pose increased risk in specific populations, such as individuals with pre-existing cardiovascular conditions or those with risk factors for glutathione depletion, such as chronic alcoholism.

How Фармацитрон Works

Фармацитрон’s pharmacodynamic mechanism is the cumulative effect of its active components, which collectively target pathways involved in thermoregulation and receptor-mediated signaling.

---

Modulating Central Prostaglandin Synthesis

Paracetamol acts primarily within the central nervous system (CNS). It inhibits the synthesis of prostaglandins (specifically PGE2) via the modulation of cyclooxygenase (COX) activity in areas of low peroxide tone. This molecular cascade results in the re-setting of the hypothalamic thermal set point, thereby influencing the regulation of core body temperature.

---

Receptor-Mediated Signaling in the Periphery

This domain involves two distinct mechanisms. Pheniramine Maleate is a competitive H1 (histamine-1) receptor antagonist, occupying H1 sites. Phenylephrine Hydrochloride is an alpha1-adrenergic receptor agonist. The H1 antagonism mitigates the effects of histamine, while alpha1-adrenergic agonism drives localized vasoconstriction; these combined actions modulate downstream physiological responses.

---

Influencing Redox and Enzyme Cofactor Systems

Ascorbic Acid (Vitamin C) influences supportive cellular biology. It participates in multiple enzymatic reactions as a cofactor and acts as an antioxidant, regulating redox states and supporting regulatory processes driven by distinct signaling patterns.

Administration Scope

The medicine is supplied as a powder for oral solution, and the approved route of administration is oral following reconstitution.

Category	Official Usage Entities
Dosing schedule (Adults)	One packet constitutes a single dose, with a maximum limit of six packets in 24 hours to control total active ingredient intake.
Frequency and timing	Dosing is intermittent and as needed, requiring a minimum 4-hour interval between consecutive administrations.
Preparation requirements	The powder must be fully dissolved in a specified volume of hot water before the solution is consumed.
Age-group rules	The product is approved for use in adults and children 12 years of age and over, with administration generally excluded for younger pediatric patients.
Special restrictions	A primary procedural constraint is the prohibition of concurrent use with other products containing Acetaminophen.

---

Resulting Procedural Structure

The official protocol defines a standardized short-term course of treatment, with the use typically restricted to no more than five to seven consecutive days. This system ensures that the administration of the single-dose unit is always preceded by the correct dissolution procedure and strictly adhered to the maximum daily frequency cap.

Instruction Classifications (High-Level)

Category	Classification
Administration method type	Oral (Reconstituted liquid)
Frequency pattern	As-needed (Intermittent use)

Research evidence / Overview of studies for Фармацитрон

Evidence for Symptomatic Relief of Common Cold and Flu-like Illness

Research exploring multi-ingredient products, such as fixed-dose combinations, is observed primarily in short-term, randomized controlled trials (RCTs). These studies are conducted on adults experiencing acute symptoms characterized by fluctuating manifestations. Researchers monitor outcomes such as overall symptom severity using patient-reported data to describe patterns observed over short time intervals.

Research Focus on Core Symptoms: Pain, Fever, and Congestion

Specific research explores how individual symptoms, including outcomes related to physical discomfort (headache and body aches) and physiological strain (fever), evolve in the observed populations. Research has also examined the measurement of change in nasal congestion. However, the scientific data for the oral decongestant component ( Phenylephrine) has been examined, and findings indicate it appears subject to uncertainty regarding its use for nasal congestion.

The Role of Each Component in Combination Studies

Studies examined the combination against a placebo to observe how symptoms change when all active ingredients are taken together. Pharmacokinetic (PK) studies in healthy volunteers monitored the presence of the components, such as Acetaminophen and Phenylephrine, in the body. Research focusing on the Ascorbic Acid component's use after symptom onset remains limited.

Follow-up Duration and Research in Specific Age Groups

The majority of clinical research focuses on periods of acute symptom activity, typically covering follow-up durations limited to 48 to 72 hours. Comprehensive data for long-term outcomes or durability of findings are not fully established. The core research was conducted on adults; while some systematic reviews include data for older children, limited information exists for special populations such as older adults or those with specific chronic conditions. The results apply only to the populations studied in the research.

What is Still Uncertain About the Evidence for Фармацитрон

A key area of uncertainty relates to the oral decongestant component, where findings were mixed and regulatory certainty remains low regarding its role in relieving nasal congestion when taken by mouth. Furthermore, subgroup findings are uncertain, as comparative evidence for groups like individuals with specific comorbidities is generally lacking. The evidence highlights what is known and what is still uncertain.

Key Studies & References

1. DailyMed Label Information: Acetaminophen, Phenylephrine HCl, Dextromethorphan HBr
2. MedlinePlus Drug Information: Acetaminophen

Common questions about Фармацитрон (FAQ)

Q: How long does the effect of Фармацитрон typically last?

A: According to the official product information, the dosing frequency is governed by a minimum interval of four hours between consecutive administrations. This interval helps to manage the total concentration of the active ingredients over time.

Q: What are the expected side effects according to official safety documentation?

A: Regulatory documents list expected adverse reactions organized by System-Organ Class. These include effects on the Nervous System, which may manifest as nervousness, sleeplessness (insomnia), or dizziness. Cardiac effects, such as increases in blood pressure or changes in heart rate, are also noted in the documentation.

Q: What are the non-directive 'use conditions' mentioned in the drug label?

A: Official guidelines describe the use as intermittent and 'as needed' for symptom relief. A primary preparation requirement is that the powder must be fully dissolved in a specified volume of hot water before the solution is consumed.

Q: Are there any studies looking at Фармацитрон use in older adults?

A: The core clinical research for this product was conducted primarily on adults. Studies and official information indicate that limited specific data exists for special populations, such as older adults, and the results apply only to the populations studied in the research.

Q: Why is proper fluid intake often mentioned alongside using Фармацитрон?

A: The required method for preparing Фармацитрон is to fully dissolve the powder in a specified volume of hot water before taking it. This dissolution step is necessary for the product's proper administration as an oral solution.

Q: Is Фармацитрон an antibiotic or antiviral medicine?

A: Official sources classify Фармацитрон as a multi-action symptomatic relief preparation. It is a fixed-dose combination of an analgesic-antipyretic (for pain and fever), a decongestant, and a vitamin supplement. It is not classified as an antibiotic or an antiviral medicine.

Q: Can Фармацитрон be taken during the daytime?

A: Official guidelines state that dosing is intermittent and intended to be taken 'as needed' for symptoms. The administration pattern is based on the required minimum four-hour interval between doses, which permits use outside of specific time restrictions.

Q: Is Фармацитрон available over the counter?

A: Yes, official product documentation refers to Фармацитрон as an over-the-counter (OTC) fixed-dose combination product.

Q: Are there any long-term side effects noted for Фармацитрон?

A: Clinical research for symptomatic relief products typically focuses on short periods of acute symptom activity. The official evidence overview indicates that comprehensive data for long-term outcomes or durability of findings for this product are not fully established.

Q: How does Фармацитрон differ from a basic pain reliever?

A: Фармацитрон is defined as a fixed-dose combination product integrating multiple active agents. Unlike a basic pain reliever (analgesic-antipyretic), it also contains a decongestant and a vitamin supplement.

Q: Can Фармацитрон be mixed with juice instead of water?

A: The official preparation requirement specifies that the powder must be fully dissolved in a specified volume of hot water before the solution is consumed. Official documentation specifies the preparation method is required for the solution's proper administration.

Q: Is there a maximum number of consecutive days recommended for using Фармацитрон?

A: The official protocol defines a standardized short-term course of treatment. The use of the product is typically restricted to no more than five to seven consecutive days.

Q: Are the effects of Фармацитрон different for children versus adults?

A: The core research for this medicine was conducted on adults, and while some systematic reviews include data for older children, the eligibility is restricted to adults and children 12 years of age and over. The results apply only to the populations studied in the research.

Q: What are the main conditions that Фармацитрон is not intended to treat?

A: Фармацитрон is intended for the symptomatic relief of the common cold and flu. Its use is officially contraindicated for individuals with conditions such as severe hepatic (liver) impairment, uncontrolled high blood pressure, and severe coronary artery disease.

How to Store and Dispose of Фармацитрон?

The officially documented storage requirements for Фармацитрон, an over-the-counter powder, focus on protecting its stability and ensuring safety.

Storage Requirements

Condition	Requirement
Temperature	Store at room temperature, away from excess heat.
Environmental	Must be protected from excess moisture and should not be stored in humid areas like the bathroom.
Packaging	Keep the medicine in its original container and ensure the container is kept tightly closed.
Child Safety	The product must be kept out of the sight and reach of children and pets at all times.

Disposal Instructions

Disposal should follow official guidelines. The preferred method is using a designated drug take-back program or mail-back option. If a program is unavailable, the medicine should be mixed with an undesirable substance (such as dirt) and placed in a sealed container before being thrown into the household trash. The medicine must not be flushed down the toilet or poured down the sink.